Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,855 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
Regulatory Filings Classification · 95% confidence The document is a press release issued by Galapagos NV announcing new clinical trial data (ATALANTA-1) presented at the ASH 2025 conference. It details specific medical study results, efficacy, and safety profiles of a drug candidate (GLPG5101). It also includes a section on the company's strategic intent to wind down cell therapy activities. This is a standard corporate announcement of clinical trial results, which falls under the 'Regulatory Filings' (RNS) category as it is a general regulatory/corporate announcement that does not fit into more specific categories like Earnings Release (ER) or Investor Presentation (IP).
2025-12-08 Dutch
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing new clinical trial data (ATALANTA-1) presented at the ASH 2025 meeting. It provides specific efficacy and safety results for a drug candidate (GLPG5101) and includes a section on the company's strategic decision to wind down its cell therapy business. As it is a corporate announcement regarding clinical trial results and business strategy, it falls under the category of general regulatory announcements/press releases.
2025-12-08 English
6-K Filing
Regulatory Filings
2025-12-08 English
Galapagos Receives Transparency Notifications from Bank of America
Major Shareholding Notification Classification · 100% confidence The document is a formal notification from Galapagos NV regarding transparency declarations received from Bank of America. It details changes in shareholding levels (crossing the 5% threshold) and provides specific tables of voting rights and financial instruments. This is a standard regulatory disclosure regarding major shareholding notifications, which falls under the 'Major Shareholding Notification' category.
2025-11-26 Dutch
Galapagos Receives Transparency Notifications from Bank of America
Major Shareholding Notification Classification · 100% confidence The document is a formal notification from Galapagos NV regarding transparency disclosures received from Bank of America. It details the crossing of a 5% voting rights threshold, providing specific data on voting rights and equivalent financial instruments held by the notifying party. This is a classic 'Major Shareholding Notification' (also known as a transparency notice in European jurisdictions), which falls under the MRQ category.
2025-11-26 English
Galapagos Receives Transparency Notifications from Bank of America
Major Shareholding Notification Classification · 100% confidence The document is a 'Transparency notification Form TR-1', which is a standard regulatory filing used in European jurisdictions to report major shareholding changes. It details the acquisition or disposal of voting rights and financial instruments by Bank of America Corporation in the issuer 'Galapagos'. This fits the definition of a 'Major Shareholding Notification' (MRQ) as it tracks the crossing of ownership thresholds.
2025-11-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.